Disease flare after EGFR tyrosine kinase inhibitor cessation predicts poor survival in patients with non-small cell lung cancer

Pathology and Oncology Research

Volumn 19, Issue 4, 2013, Pages 833-838

  Chen, Hua Jun ^a   Yan, Hong Hong ^a   Yang, Jin Ji ^a   Chen, Zhi Hong ^a   Su, Jian ^a   Zhang, Xu Chao ^a   Wu, Yi Long ^a,b  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b FACS   (China)

Author keywords

Cessation; Disease flare; Epidermal growth factor receptor; Non small cell lung cancer; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER MORTALITY; CANCER SURVIVAL; CHINESE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG WITHDRAWAL; DYSPNEA; EGFR GENE; EXON; FEMALE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT PLEURA EFFUSION; OVERALL SURVIVAL; PREDICTION; PREVALENCE; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TUMOR FLARE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PREVALENCE; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84885175670     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-013-9651-z     Document Type: Article

References (26)

1. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957
2. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121-128
3. Zhou CC, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735-742
4. Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol 13:239-246
5. Bean J, Brennan C, Shih JY et al (2007) MET amplification occurs with or without T790M mutation in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104:20932-20937
6. Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043
7. Pao W, Miller VA, Politi KA et al (2005) Acquired resistance of lung adenocarcinoma to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PloS Med 2:e73
8. Oxnard GR, Arcila ME, Sima CS et al (2011) Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 17:1616-1622
9. Ettinger DS, Akerley W, Bepler G et al (2010) Non-small cell lung cancer. J Natl Compr Canc Netw 8:740-801
10. Chaft JE, Oxnard GR, Sima CS et al (2011) Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 17:6298-6303
11. Kim YH, Fukuhara A, Mishima M (2011) Should epidermal growth factor receptor-tyrosine kinase inhibitor be continued beyond progressive disease? Case Rep Oncol 4:470-474
12. Beasley MB, Brambilla E, Travis WD (2005) The 2004 world health organization classification of lung tumors. Semin Roentgenol 40:90-97
13. Detterbeck FC, Boffa DJ, Tanoue LT (2009) The new lung cancer staging system. Chest 136:260-271
14. Lee YJ, Choi HJ, Kim SK et al (2010) Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with non-small-cell lung cancer. Cancer 116:1336-1343
15. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
16. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
17. Zhou Q, Zhang XC, Chen ZH et al (2011) Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 29:3316-3321
18. Riely GJ, Kris MG, Zhao B et al (2007) Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13:5150-5155
19. Omuro AM, Kris MG, Miller VA et al (2005) High incidence of disease recurrence in the brain and leptomeninges in patients with non-small cell lung carcinoma after response to gefitinib. Cancer 103:2344-2348
20. Penel N, Brichet A, Prevost B et al (2001) Prognostic factors of synchronous brain metastases from lung cancer. Lung Cancer 33:143-154
21. Ampil F, Caldito G, Milligan S et al (2007) The elderly with synchronous non-small cell lung cancer and solitary brain metastasis: does palliative thoracic radiotherapy have a useful role? Lung Cancer 57:60-65
22. Sharma SV, Lee DY, Li B et al (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141:69-80
23. Becker A, Crombag L, Heideman DA et al (2011) Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur J Cancer 47:2603-2606
24. Heon S, Nishino M, Goldberg SB et al. (2012) Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR-mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance. In: ASCO Annual Meeting [Abstract 7525]
25. Mitsudomi T, Morita S, Yatabe Y et al. (2012) Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). In: ASCO Annual Meeting [Abstract 7521]
26. Zhou CC, Wu YL, Liu XQ et al. (2012) Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). In: ASCO Annual Meeting [Abstract 7520]